Pramipexole

BOSTON — Treatment with an investigational combination of low-dose pramipexole and rasagiline led to less excessive daytime sleepiness and fewer adverse events compared with pramipexole alone in early Parkinson’s disease, research showed.

Pharma Two B, a company that uses reformulations and combinations of previously approved drugs to develop new therapies for neurological indications, announced its novel therapy for Parkinson’s disease met primary and secondary endpoints.